IGNE Igene Biotechnology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IGNE Igene Biotechnology

IGNE 0.00001000

0.0%

Mar 6 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Dwayne Hines	1/16/2010 12:06:29 PM
	of 209

Good news - it appears that Novartis is an investor in Igene's joint venture with Archer Daniels. "Forma could receive up to $200 million in up-front and milestone payments in exchange for developing inhibitors for a protein-protein interaction target relevant in cancer. Novartis Option Fund is also an investor in Forma. and have formed a joint venture, Naturxan, to make astaxanthin, a pigment used to color farm-raised salmon and other fish. Chemical & Engineering News, 87(3), January 19, 2009 [TOC]" That might explain why Naturxan hired a heavy hitter like Rick Grelewicz from Bristol Myers Squibb - Mead Johnson Nutritionals to run the joint venture. Grelewicz's background in nutritionals suggest that the product will be marketed for humans as well as fish.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next